Superior Planning, LLC’s Tarsus Pharmaceuticals TARS Stock Holding History

Superior Planning, LLC’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$236	Buy	+3	New	+$208	﹤0.01%	2019

Other funds holding TARS

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return

Superior Planning, LLC's TARS Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Tarsus Pharmaceuticals (TARS) in Q3 2026: 3 shares worth $236. The stake represents ﹤0.01% of the portfolio and ranks #2019 among its holdings.

139 funds tracked by Wall St. Rank hold TARS as of Q3 2026.

Superior Planning, LLC held 3 shares of Tarsus Pharmaceuticals worth $236 as of Q3 2026.
Tarsus Pharmaceuticals was a new Superior Planning, LLC position in Q3 2026.
Tarsus Pharmaceuticals made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #2019 holding.
139 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.